We are here to help.
(888) 237-9017(888) 237-9017

California Woman Claims Eliquis Side Effects Caused Bleeding, Hospitalization

In a recent Eliquis lawsuit, a woman claims that drug makers Bristol-Myers Squibb and Pfizer misled her and her doctors about the safety of this medication, which caused her to suffer severe gastrointestinal bleeding and prolonged hospitalization.

Carol Woody filed her Eliquis lawsuit on April 24 in Delaware Superior Court, naming her husband, Jake Woody, as co-plaintiff. According to Woody’s complaint, she suffered severe injuries which required extensive medical treatment and hospitalization after taking Eliquis, which she says she was led to believe was safe. On the contrary, Woody claims, the risk of uncontrollable Eliquis bleeding and the lack of an antidote make this drug inherently dangerous.

Eliquis (apixaban) is one of a newer generation of blood thinners (anticoagulants) called Factor Xa inhibitors. These medications may help to prevent blood clots in individuals with atrial fibrillation, who have recently had surgery, or who show other risk factors for dangerous clots. Since the 1950s, warfarin (Coumadin) has been the go-to blood thinner, but when drugs like Eliquis, Xarelto, and Pradaxa reached the market many doctors and patients saw them as superior alternatives.

Part of the popularity of Eliquis and other Factor Xa inhibitors may now be attributed by some to direct-to-consumer advertising by drug makers who promoted the newer drugs as more convenient than warfarin. Patients taking warfarin often need to re-adjust their dosages, which they learn through routine blood monitoring. With Eliquis and related drugs, it was believed that the standardized dosing meant that no blood monitoring was required. Another reason drugs like Eliquis may have been especially appealing to consumers is that warfarin was used so commonly and for so many years that its risk of internal bleeding side effects was well-known. Now, some claim that they were led to believe that this risk was lower with Eliquis and other Factor Xa inhibitors.

Unfortunately, it now appears that consumers who believed Eliquis was safer than warfarin may have been gravely misled or misinformed. All anticoagulants are designed to prevent blood clots, which means that they all carry a risk of internal bleeding. Furthermore, patients now claim that they may have chosen a different blood thinner had they known that there is no reversal agent, or antidote, to stop Eliquis internal bleeding. With warfarin patients, bleeding may be addressed with a timely dose of Vitamin K.

In her Eliquis lawsuit, Carol Woody says that she was prescribed this medication to prevent blood clots potentially resulting from her atrial fibrillation. In November 2014, she suffered severe gastrointestinal hemorrhage and internal bleeding that caused her to require "extensive blood transfusions and extended hospitalization."

According to Woody’s claim, Bristol-Myers Squibb and Pfizer knew or should have known of Eliquis internal bleeding risks and they misrepresented the safety of this drug to regulators, doctors, and patients. Woody also claims that the drug makers were negligent in failing to make the lack of a reversal agent for Eliquis bleeding clear. She says, "In written information about the safety and risks of Eliquis, Defendants negligently and fraudulently represented to the medical and healthcare community, including Plaintiff’s prescribing doctor, the Food and Drug Administration (hereinafter referred to as the ‘FDA’), to Plaintiff and the public in general, that Eliquis had been tested and was found to be safe and effective for its indicated uses. Defendants concealed their knowledge of Eliquis’ defects, from Plaintiff, the FDA, the public in general and the medical community, including Plaintiff’s prescribing doctor."

Woody goes on to claim that the drug makers’ actions regarding their alleged misrepresentation of Eliquis were "callous, reckless, willful, depraved indifference to health, safety, and welfare of the Plaintiff."

This Eliquis lawsuit was filed in Delaware Superior Court, so it will not join the growing number of federal Eliquis lawsuits centralized as a multidistrict litigation (MDL) before U.S. District Judge Denise L. Cote in the Southern District of New York. Nevertheless, rulings in the Eliquis MDL may impact claims filed in state courts, and vice versa.

If you believe that you or someone you love was injured as a result of drug makers’ misrepresentation of Eliquis or Xarelto side effects, we can help you determine whether you are entitled to compensation. Please contact our attorneys for a free evaluation of your claim.